Decheng Capital led a $102m Series A round in Baylor Genetics.

Synopsis

Decheng Capital, an investment firm, led a $102m Series A round in Baylor Genetics, a diagnostic genomics company.

Principals

Baylor Genetics

Decheng Capital

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (2)

kengo takishima

CEO at BAYLOR GENETICS

Manager

target

Deal

£ 79 M

Total Value

cheston larson

Partner at Latham & Watkins

Lawyer

target

Deals

£ 20.02 B

Total Value

Bidder Team (1)

xiangmin cui

‎Founder and Managing Partner at DECHENG CAPITAL LLC

Investor

bidder

Deals

£ 6.27 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy